07:01 AM EDT, 09/25/2025 (MT Newswires) -- Eli Lilly and Company ( LLY ) 's Kisunla has been granted EU marketing authorization by the European Commission to treat mild cognitive impairment associated with Alzheimer's disease in certain patients, the authority said Thursday.

The authorization is based on the positive scientific assessment of the European Medicines Agency, the European Commission said, adding that it has set strict conditions on the use of Kisunla as it is only deemed suitable for patients with a particular genetic disposition.